Carlo F Perno
Overview
Explore the profile of Carlo F Perno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Antilici L, Vittucci A, Cristaldi S, Musolino A, Pisani M, Rotondi Aufiero L, et al.
Pediatr Pulmonol
. 2024 Oct;
60(1):e27358.
PMID: 39451018
Background: In the last decades none of the medical therapies investigated have shown clear efficacy in the treatment of bronchiolitis, and literature agrees on a general de-implementation of pharmacological therapies,...
2.
Bottari G, Paionni E, Fegatelli D, Murciano M, Rosati F, Ferrigno F, et al.
Pediatr Crit Care Med
. 2024 Jul;
25(10):937-946.
PMID: 39023339
Objectives: Blood level of pancreatic stone protein (PSP) is a promising biomarker of sepsis both in adults and children. The aim of our study was to investigate the diagnostic accuracy...
3.
Orkin C, Schapiro J, Perno C, Kuritzkes D, Patel P, DeMoor R, et al.
Clin Infect Dis
. 2023 Jun;
77(10):1423-1431.
PMID: 37340869
Background: Previously reported post hoc multivariable analyses exploring predictors of confirmed virologic failure (CVF) with cabotegravir + rilpivirine long-acting (CAB + RPV LA) were expanded to include data beyond week...
4.
Cento V, Colagrossi L, Bossi I, Armenia D, Nava A, Piccinelli E, et al.
Minerva Med
. 2022 Oct;
114(3):289-299.
PMID: 36255708
Background: Acute coronary syndromes (ACS) are a major cause of morbidity and mortality. As cytomegalovirus (CMV) may contribute to cardio-vascular (CV) manifestations, we sought to provide a proof-of-concept for the...
5.
Armenia D, Forbici F, Bertoli A, Berno G, Malagnino V, Gagliardini R, et al.
J Glob Antimicrob Resist
. 2022 Jul;
30:326-334.
PMID: 35793776
Objectives: We evaluated virological response and resistance profiles in individuals who were virologically suppressed who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in real life. Methods: Survival analysis was used to assess...
6.
Ammirati E, Varrenti M, Veronese G, Fanti D, Nava A, Cipriani M, et al.
Eur J Heart Fail
. 2021 May;
23(7):1242-1245.
PMID: 34036693
No abstract available.
7.
Cutrell A, Schapiro J, Perno C, Kuritzkes D, Quercia R, Patel P, et al.
AIDS
. 2021 Mar;
35(9):1333-1342.
PMID: 33730748
Objective: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with...
8.
Caruso A, Caccuri F, Bugatti A, Zani A, Vanoni M, Bonfanti P, et al.
J Med Virol
. 2020 Sep;
93(3):1780-1785.
PMID: 32926453
In early 2020 the new respiratory syndrome COVID-19 (caused by the zoonotic SARS-CoV-2 virus) spread like a pandemic, starting from Wuhan, China, causing severe economic depression. Despite some advances in...
9.
Sorbo M, Carioti L, Bellocchi M, Antonucci F, Sforza D, Lenci I, et al.
Liver Int
. 2019 Jun;
39(10):1986-1998.
PMID: 31172639
Background & Aims: We investigated the HCV-RNA amount, variability and prevalence of resistance-associated substitutions (RASs), in plasma, hepatic tumoral and non-tumoral tissue samples in patients undergoing liver-transplant/hepatic-resection (LT/HR), because of...
10.
Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, et al.
Antivir Ther
. 2019 Apr;
24(5):321-331.
PMID: 30977466
Background: Pre-cART (combined antiretroviral therapy) plasma viral load >500,000 copies/ml has been associated with a lower probability of achieving virological suppression, while few data about its role on maintenance of...